Abstract: The present disclosure relates to composition comprising pooled and expanded allogeneic mesenchymal Stromal cells (MSCs) and a method for management of Ischemia using the composition thereof. In particular, the disclosure relates to bone marrow derived pooled and expanded allogeneic MSC compositions with effective dosage ranges and modes/route of administration for effective management of Ischemia. The disclosure also relates to the use of conditioned medium rich in bioactive factors in combination with the cell composition for managing ischemic conditions.

Abstract: The present disclosure relates to composition comprising pooled and expanded allogeneic mesenchymal Stromal cells (MSCs) and a method for management of Ischemia using the composition thereof. In particular, the disclosure relates to bone marrow derived pooled and expanded allogeneic MSC compositions with effective dosage ranges and modes/route of administration for effective management of Ischemia. The disclosure also relates to the use of conditioned medium rich in bioactive factors in combination with the cell composition for managing ischemic conditions.

Abstract: The present disclosure relates to a conditioned medium (CM) enriched with bioactive factor, its composition and the method of producing the CM. The method of obtaining the desired quantity of bioactive factors in conditioned medium comprises of pooling bone marrow derived mesenchymal stromal/stem cells, culturing the pooled cell and subjecting the cell culture to a cell feeding schedule at specified confluency and collecting the potent conditioned medium rich in bioactive factors at specific passage/time period. The method further aims at maximizing the probability of generating a conditioned medium with reduced biological variability and comprising large number of bioactive factors having specific biological function/property. The disclosure also relates to composition and formulation of the conditioned medium and their use in cosmetic and therapeutic areas.

Abstract: The present disclosure relates to a composition and method for management of Osteoarthritis, including improvement in pain and cartilage regeneration of knee joint affected by osteoarthritis. The present disclosure also relates to a kit for treating Osteoarthritis and the method of assembling the same. The present disclosure relates to a pooled allogeneic mesenchymal stromal cell composition from multiple donors with diverse HLA genotypes suitable for transplantation into a diverse population without the risk of rejection. The pooled cell composition of the present disclosure shows increased potency and higher chondrogenic differentiation potential.

Abstract: The present invention discloses a method of isolation, pooling and further culturing of Mesenchymal Stem cells (MSC) for clinical application. Present invention also discloses the method of establishing Master Cell bank, followed by Working Cell Bank from which the final therapeutic composition referred to as Investigational Product/Investigational Medicinal Product comprising of allogenic bone marrow-derived MSC is formulated for clinical applications. Present disclosure also discloses a robust manufacturing process for consistent production of clinical grade Mesenchymal Stromal cells (MSCs). The process enables production of highly viable potent cells. The process steps relating to preparation of media, cell seeding, harvesting are fine tuned to achieve consistency in cell yield, superior cell viability, purity, improved cell proliferation, high cell recovery, low HLA-DR expression, reduction in culture duration.